Skip to content

The effects of continuous use of Dr. Yu AD cream for 4 weeks on lipid secretion and microecology in normal subjects and patients with rosacea: a clinical trial

The effects of continuous use of Dr. Yu AD cream for 4 weeks on lipid secretion and microecology in normal subjects and patients with rosacea: a clinical trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073735
Enrollment
Unknown
Registered
2023-07-19
Start date
2020-03-30
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rosacea

Interventions

control group:Dr. Yu AD cream
rosacea group:Dr. Yu AD cream

Sponsors

Shanghai Skin Disease Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Healthy adult female aged 18-45; subjects who are willing to participate in the trial and are able to complete skin tests as required throughout the study; subjects who have read and signed the informed consent form before the study began; subjects who are healthy at the time of the test; subjects who can complete the prescribed content as required by the test plan; patients with mild to moderate rosacea should stop macrolides or retinoids for at least 6 weeks and related antibiotics, hormones, or calcineurin inhibitors for at least 4 weeks.

Exclusion criteria

Exclusion criteria: Pregnant and lactating women; patients with severe allergic diseases or who have been allergic to cosmetics in the last one to two years; subjects who enrolled in any other drug within three months before the trial began; Regular users of Chinese herbs, sleeping pills, sedatives, tranquilizers, or other addictive drugs; alcoholics, mental patients; or can not follow the doctor's advice to cooperate with the treatment; patients with cardiopulmonary insufficiency and serious underlying diseases; subjects who have other skin conditions that may interfere with the clinical evaluation of acne-like skin and/or put the subject at risk, or have a history of other severe skin conditions; subjects who the researchers believe are unable to participate for other reasons.

Design outcomes

Primary

MeasureTime frame
Moisture content of skin stratum corneum;Skin water loss through epidermis TEWL;Microecological detection;LL-37 detection;Substance P detection;

Secondary

MeasureTime frame
Adverse event;

Countries

China

Contacts

Public ContactChao Yuan

Shanghai Skin Disease Hospital

dermayuan@163.com+86 180 1733 6863

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026